Incidência de Interações Medicamentosas e Avaliação Clínica nos Pacientes de um Hospital Público Brasileiro
DOI:
https://doi.org/10.17921/1415-6938.2020v24n3p202-210Resumo
Interações droga-droga (IDDs) são responsáveis por problemas terapêuticos e as principais causas de reações adversas a medicamentos que levam a hospitalização. O objetivo do trabalho foi analisar a incidência de IDDs em pacientes admitidos em hospital público no Brasil, em 2015. Em um estudo transversal, 351pacientes foram selecionados com IDDs utilizando-se o banco de dados da Micromedex®, e as interações foram classificadas de acordo com a severidade e documentação. Os potenciais IDDs foram avaliados durante o acompanhamento farmacoterapêutico diário por anamnese farmacêutica e a análise dos exames laboratoriais foi realizada. Um total de 2.937 potenciais IDDs foram identificados e 28,42% deles tinham sinais e sintomas clínicos confirmados em 87 pacientes (29%). Entre os pacientes que apresentaram interações, 62,07% tinham mais que 60 anos. Neste grupo de idade, 61,27% de todos os sinais e sintomas clínicos observados foram também identificados, demonstrando uma associação positiva entre interações clínicas e idade. Além disso, uma correlação positiva entre o número de drogas prescritas e a ocorrência de sinais clínicos também foram observados. Muitos IDDs observados foram de severidade moderada e estavam relacionados a alterações das pressões arteriais e níveis glicêmicos. Este estudo demonstrou que IDDs estão diretamente relacionados a idade e número de drogas prescritas. E a grande frequência de IDDs com documentação fraca alertam para a necessidade de se analisar esse tipo de interação. Sendo assim, este estudo mostrou que potenciais IDDs e sinais e sintomas clínicos significantes em pacientes só reforçam a necessidade de se apoiar a farmácia clínica.
Palavras-chave: Interação Droga-Droga (IDD). Pacientes Internados. Farmacoterapia, Poli Farmácia. Sinais e Sintomas.
Abstract
Drug-drug interactions (DDIs) are responsible for therapeutic problems and the main causes of adverse drug reactions that require hospitalization. The aim of this study was to analyze the incidence of DDIs in patients admitted in a Public Hospital in Brazil, in 2015.
In a cross-sectional study, DDIs were screened in 351 patients, using Micromedex® database, that classify interactions according to severity and documentary evidence. Potential DDIs were assessed at the daily pharmacotherapeutic follow-up through pharmaceutical anamnesis and analysis of laboratory tests were performed. A total of 2,937 potential DDIs were identified and 28.42% of these had confirmed signs and symptoms clinical in 87 patients (29%). Among the patients that presented interactions, 62.07% were older than 60 years. In this age group, 61.27% of all signs and symptoms clinical observed in the study were also identified, demonstrating a positive association between the occurrence of clinical interactions and age. In addition, a positive correlation between the number of drugs prescribed and the occurrence of signs clinicals was also observed. Most DDIs observed were of moderate severity and were related to imbalance of blood pressure and glycemic levels. This study demonstrated that DDIs are directly related to the age and number of drugs prescribed. And the greater frequency of DDIs with fair documentary evidence alerts to the need to consider all the possible interactions. Thereafter, this study showed that potential DDIs and sign and clinical symptoms are significant in patients and reinforce the need to support Clinical Pharmacy.
Keywords: Drug-Drug Interaction (DDI). Inpatients. Pharmacotherapy. Poly Pharmacy. Sign and Symptom.
Referências
ANDRADE, P.H.S.; LOBO, I.M.F.; DA SILVA, W.B. Risk factors for adverse drug reactions in pediatric inpatients: A cohort study. PLoS One. v.12, p.e0182327, 2017.
ASTRAND, B. et al. Detection of potential drug interactions - a model for a national pharmacy register. Eur. J. Clin. Pharmacol. v.62, p.749-56, 2006.
BAHAR, M.A. et al. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. v.18, p.701-739, 2017.
BURKE, A.; SMYTH, E.; FITZGERALD, G. Analgésicos-antipiréticos: farmacoterapia da gota. In: Brunton LL, Lazo JS, Parker KL (ed) Goodman & Gilman: as bases farmacológicas da terapêutica. 11th edn. McGraw-Hill, Rio de Janeiro, 2006.
CASTILHO, E.C.D. et al. Potential drug-drug interactions and polypharmacy in institutionalized elderly patients in a public hospital in Brazil. J. Psychiatr. Ment. Health Nurs. v.25, p.3-13, 2018.
CRUCIOL-SOUZA, J.M.; THOMSON, J.C. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. v.61, p:515-520, 2006.
DAI, D. et al. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U.S. Children's Hospitals. Pediatr. Crit. Care Med. v.17, p.e218, 2016.
DALLENBACH, M.F. et al. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM. v.100, p.691-697, 2007.
DE OLIVEIRA ALVES, C.; SCHUELTER-TREVISOL, F.; TREVISOL, D.J. Beers criteria-based assessment of medication use in hospitalized elderly patients in southern Brazil. J. Family Med. Prim. Care. v.3, p.260-265, 2014.
DOAN, J. et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann. Pharmacother. v.47, p.324-332, 2013.
DOYLE, M.E.; EGAN, J.M. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. v.55, p.105-131, 2003.
FDA, Food and Drug Administration. Cipro(R) XR oral extended release tablets, ciprofloxacin oral extended release tablets. Bayer HealthCare Pharmaceuticals, Wayne, 2013b. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021473Orig1s000Approv.pdf
FDA, Food and Drug Administration. Procardia XL(R) oral extended release tablets, nifedipine oral extended release tablets. Pfizer Labs, New York, 2013a. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019684s029lbl.pdf
GOSNEY, M,; TALLIS, R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet. v.8402, p.564-567, 1984.
HAMMAD, M.A. et al. Drug-drug interaction-related uncontrolled glycemia. J. Pharm. Bioallied. Sci. v.9, p.221-228, 2017.
HOSIA-RANDELL, H.M.; MUURINEN, S.M.; PITKÄLÄ, K.H. Exposure to potentially inappropriate drugs and drug-drug interactions in elderly nursing home residents in Helsinki, Finland: a cross-sectional study. Drugs Aging. v.25, p.683-692, 2008.
HUSSAR, D.A. Interações Medicamentosas. In: Gennaro AR (ed) A ciência e a prática da farmácia. 20th edn. Guanabara Koogan, Rio de Janeiro, 2000.
JACKSON, E.K. Diuréticos. In: Brunton LL, Lazo JS, Parker KL (ed) Goodman & Gilman: as bases farmacológicas da terapêutica. 11th edn. McGraw-Hill, Rio de Janeiro, 2006b.
JACKSON, E.K. Renina e angiotensina. In: Brunton LL, Lazo JS, Parker KL (ed) Goodman & Gilman: as bases farmacológicas da terapêutica. 11th edn. McGraw-Hill, Rio de Janeiro, 2006a.
JAIN, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl. Acad. Sci. v.114, p.944-949, 2017.
JANCHAWEE, B. et al. Pharmacoepidemiologic study of potential drug interactions in outpatients of a university hospital in Thailand. J. Clin. Pharm. Ther. v.30, p.13-20, 2005.
JAZBAR, J. et al. Clinically relevant potential drug–drug interactions among outpatients: A nationwide database study. Res. Social Adm. Pharm. v.14, p.572-580, 2018.
KANNAN, G. et al. A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital. J. Postgrad. Med. v.57, p.206-210, 2011.
KEINE, D. et al. Polypharmacy in an elderly population: enhancing medication management through the use of clinical decision support software plataforms. Neurol. Ther. v.19, p.1-16, 2019.
LAFATA, J.E. et al. Potential drug-drug interactions in the outpatient setting. Med. Care. v.44, p.534-541, 2006.
LIMA, R.E.F.; CASSIANI, S.H.B. Potential drug interactions in intensive care unit patients at a university hospital. Rev. Latino-Am. Enfermagem. v.17, p.222-227, 2009.
LIN, C.F. et al. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging. v.28, p.219-225, 2011.
LING, Y.; SALEEM, W.; SHEE, C.D. Concomitant use of β-blockers and β2-agonists. Eur. Respir. J. v.31, p.905-906, 2008.
LÓPEZ-PICAZO, J.J. et al. Escala de peligro para interacción grave: una herramienta para la priorización de estrategias de mejora em la seguridad de la prescripción en medicina de família. Aten Primaria. v.43, p.254-262, 2011.
MARENGONI, A. et al. Understanding adverse drug reactions in older adults through drug–drug interactions. Eur. J. Intern. Med. v.25, p.843–846, 2014.
MICROMEDEX R Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically, 2016. Available from: https://rdl.lib.uconn.edu/databases/919
MIGUEL, A. et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. v.21, p.1139–1154, 2012.
MILFRED-LAFOREST, S.K. et al. Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network. J. Card. Fail. v.19, p.354-369, 2013.
MORIVAL, C. et al. Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining. Eur. J. Clin. Pharmacol. v.74, p.525-534, 2018.
MOURA, C.S.; ACURCIO, F.A.; BELO, N.O. Drug-drug interactions associated with length of stay and cost of hospitalization. J. Pharm. Sci. v.12, p.266-272, 2009.
NABOVATI, E. et al. Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature. DARU. v.22, p.52, 2014.
PATERNO, M.D. et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J. Am. Med. Inform. Assoc. v.16, p.40-46, 2009.
PENG, C.C. et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J. Manag. Care Pharm. v.9, p.513-522, 2003.
PHANSALKAR, S. et al. High-priority drug-drug interactions for use in electronic health records. J. Am. Med. Inform. Assoc. v.19, p.735-743, 2012.
REIMCHE, L.; FORSTER, A.J.; WALRAVEN, C.V. Incidence and contributors to potential drug-drug interactions in hospitalized patients. J. Clin. Pharmacol. v.51, p.1043-1050, 2011.
RHEE, E.G. et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a β-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants. Antimicrob. Agents Chemother. v.62, p.e00280-18, 2018.
RIECHELMANN, R.P. et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother. Pharmacol. v.56, p.286-290, 2005.
ROBLEK, T. et al. Clinical-pharmacist intervention reduces clinically significant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial. Int. J. Cardiol. v.203, p.647-652, 2016.
SHARMA, S.; CHHETRI, H.P.; ALAM, K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J. Pharmacol. v.46, p.152-156, 2014.
SHI, J.Y. et al. Detecting drug communities and predicting comprehensive drug-drug interactions via balance regularized semi-nonnegative matrix factorization. J. Cheminform. v.11, p.28, 2019.
SÖNNERSTAM, E. et al. Clinically relevant drug-drug interactions among elderly people with dementia. Eur. J. Clin. Pharmacol. v.74, p.1351-1360, 2018.
TATUM, T. et al. Polypharmacy rates among patients over 45 years. Ir. Med. J. v.112, p.893, 2019.
TERLEIRA, A. et al. Effect of drug-test interactions on length of hospital stay. Pharmacoepidemiol. Drug Saf. v.16, p.39-45, 2007.
ZHOU, D. et al. Simulation and prediction of the drug–drug interaction potential of naloxegol by physiologically based pharmacokinetic modeling. CPT Pharmacomet. Syst. Pharmacol. v.5, p.250–225, 2016.
